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Abstract
Background: FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant
FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated.
Methods: We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with
BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary
endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate,
and grade III–IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and ana-
lyzed using the Kaplan-Meier method.
Results: We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with
FOLFIRINOX. Most studies (n¼20) presented intention-to-treat results. The median number of administered neoadjuvant
FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] ¼ 60.1% to 74.6%), and the
R0-resection rate was 83.9% (95% CI ¼ 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-
level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months
(95% CI ¼ 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI ¼ 14.5 to 21.5
months). Pooled event rates for grade III–IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI ¼
10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI ¼ 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI ¼ 8.1 to 14.2).
No deaths were attributed to FOLFIRINOX.
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Conclusions: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable
median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.
Pancreatic cancer is expected to be the second-leading cause of
cancer-related death by 2030 (1). Approximately 20% of patients
have borderline resectable pancreatic cancer (BRPC) or upfront
resectable pancreatic cancer at diagnosis (2). Even after
curative-intent surgery, cure is exceedingly rare, as demon-
strated by a 10-year overall survival (OS) of 4% (3). Upfront resec-
tion with adjuvant chemotherapy has long been the standard of
care for patients with localized pancreatic cancer. However, due
to postoperative complications, deteriorating performance sta-
tus, and early progressive disease, only about 55% of patients re-
ceive adjuvant chemotherapy (4–6). With a neoadjuvant
approach, almost all patients receive systemic chemotherapy.
This approach aims to address occult metastatic disease, in-
crease the rate of R0 resection, and avoid futile surgery in
patients with rapidly progressive disease (7) .
Several neoadjuvant treatment regimens with or without
chemoradiotherapy (CRT) have been proposed for BRPC patients
(8–10). A combination chemotherapy regimen of folinic acid
(leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin
(FOLFIRINOX) seems to be the most effective regimen for
patients with pancreatic cancer. In a randomized, controlled
trial (RCT), patients with metastatic pancreatic cancer had a su-
perior OS with FOLFIRINOX compared with gemcitabine (me-
dian 11.1 vs 6.8 months, P< .001) (11). No RCT has been
published with FOLFIRINOX in the neoadjuvant setting for BRPC
patients. All published phase I–II trials and cohort studies on
neoadjuvant FOLFIRINOX for BRPC patients are small and there-
fore report a wide range of median OS (12–15).
The primary aim of this systematic review and patient-level
meta-analysis was to determine OS after neoadjuvant
FOLFIRINOX as first-line treatment for patients with BRPC.
Secondary outcomes included progression-free survival (PFS),
resection rate, R0 resection rate, and grade III–IV adverse events
(AEs).
Methods
Eligibility
We searched for studies containing treatment-naı¨ve patients
with BRPC treated with FOLFIRINOX as neoadjuvant therapy, ir-
respective of further treatment after FOLFIRINOX. Case reports,
reviews, letters to the editor, conference abstracts without full
text, and studies only reporting on specific groups of patients
(eg, only patients in a specific age group) were excluded.
Search Strategy
This systematic review was performed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis standard guidelines (16). To identify relevant studies, a
comprehensive librarian-led search of Embase, MEDLINE (via
OvidSP), Web of Science, Scopus, Cochrane Central, and Google
Scholar was performed on September 1, 2017. Search terms in-
cluded “FOLFIRINOX,” “folinic acid,” “fluorouracil,” “irinotecan,”
“oxaliplatin,” “pancreas cancer,” “drug combination,” and rele-
vant variants thereof. Only articles written in English were
assessed. No restrictions on publication date were applied.
Literature without formal publication was not assessed. A full
description of the search is summarized in the Supplementary
Methods (available online).
Selection Procedure and Data Collection
After removal of duplicates, Q. P. Janssen and S. Buettner inde-
pendently reviewed the abstracts for eligibility. The full-text arti-
cle of any study that met the inclusion criteria was retrieved for
further assessment. Full-text studies were excluded if only a reg-
imen other than FOLFIRINOX was used, if the study did not in-
clude at least one BRPC patient, if the study was not an original
report, or if the same patient cohort was presented in another
study. Disagreements were resolved through discussion and
consensus. Q. P. Janssen and S. Buettner extracted the data from
selected studies with use of standardized data collection forms.
The primary outcome was OS. Secondary outcomes were PFS, re-
section rates, R0 resection rates, and Common Terminology
Criteria for Adverse Events grade III–IV (17). Other collected data
included study characteristics (first author, year of publication,
study design, inclusion period, duration of follow-up), study
population specifications (total sample size, number of patients
treated with FOLFIRINOX in total and per disease stage), and
details on the intervention (FOLFIRINOX regimen, number of ad-
ministered cycles, other treatments).
For the patient-level meta-analysis, we contacted the
authors of all studies to obtain (updated) patient-level data on
OS and PFS. Data were collected for BRPC patients only. The
authors of four studies (14,18–20) provided patient-level data for
additional BRPC patients not included in the reviewed articles.
Data other than OS and PFS were not collected at the patient
level but reported as aggregate outcomes from the published
studies.
Methodological Assessment
All studies were assessed for risk of bias using an appraisal sys-
tem developed by the Critical Appraisal Skill Program (21). This
critical appraisal tool is designed to systematically assess the
methodology of individual studies. Publication bias was assessed
with a funnel plot (22).
Statistical Analysis
Patient-level survival outcomes were analyzed with the Kaplan-
Meier method using the rms and survival packages for R 3.5.0
(https://cran.r-project.org/). The Kaplan-Meier method was used
to account for censoring of patients alive or without recurrence
at last follow-up. The primary survival outcome was OS, and
the secondary outcome was PFS. Median, 1-year, 3-year, and 5-
year survival were analyzed and reported for OS, and median, 1-
year, 2-year, and 3-year for PFS. Patient-level survival outcomes
were calculated from treatment initiation. One study only
reported the date of surgery; therefore, 11 weeks were added to
the date of surgery to account for a median of four cycles of
FOLFIRINOX (8 weeks) with an additional 3-week interval to sur-
gery (18). We performed post-hoc sensitivity analyses on
patient-level survival data after exclusion of studies including
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only patients who underwent a resection after neoadjuvant
therapy, comparing retrospective and prospective studies, com-
paring studies in which the number of FOLFIRINOX cycles was
at least six or less than six, comparing studies using full-dose or
modified FOLFIRINOX regimens, comparing studies with or
without granulocyte-colony stimulating factor (G-CSF) primary
prophylaxis, analyzing the influence of (neo)adjuvant (chemo)-
radiation therapy after neoadjuvant FOLFIRINOX on survival,
and including only patients who were recurrence-free after
12 months. Survival distributions were compared using the log-
rank test. The 95% confidence intervals (CI) for survival esti-
mates at 1, 2, 3, and 5 years were calculated using a log(log
S^(t)) transformation.
Pooled proportions of resection and R0 resection were calcu-
lated. The I2 statistic was estimated for both proportions to as-
sess whether observed differences in proportions were
compatible with chance alone or partly attributable to heteroge-
neity. The I2 statistic estimates the percentage of variation
across studies that can be ascribed to heterogeneity rather than
chance (23). An I2 above 50% is considered substantial heteroge-
neity (24). Random-effects models rather than fixed-effects
models were used because heterogeneity in the definitions of
disease stage across studies was anticipated to cause heteroge-
neity in the proportion of resection and R0 resection (23).
Studies only reporting data for BRPC patients who underwent a
resection after neoadjuvant FOLFIRINOX were included only for
the analysis of R0 resection rates, not for overall resection rates.
Grade III or IV AEs were calculated as number of events per 100
patients and pooled in random-effects models. AEs were pooled
separately for prospective and retrospective studies. We per-
formed a subgroup analysis comparing grade III or IV event
rates of neutropenia and febrile neutropenia in studies with or
without G-CSF prophylaxis. Pooled analyses were performed us-
ing the meta package for R 3.5.0. All tests were two-sided. A P
value less than .05 was considered statistically significant.
Results
Included Studies
We identified 2659 potentially relevant studies. Based on the
abstracts, 54 studies were selected for full-text assessment, of
which 24 studies (representing 1802 patients) fulfilled all inclu-
sion criteria (Figure 1) . Ten studies were excluded because only
regimens other than FOLFIRINOX were used, 15 studies because
no BRPC patients were included, 2 studies because the article
was written in a language other than English, 1 study was a pro-
tocol, and 2 studies overlapped with other included studies
(Supplementary Methods, available online).
Table 1 shows the study characteristics. Resectability status
was defined by National Comprehensive Cancer Network crite-
ria (42) in eight studies, Americas Hepato-Pancreato-Biliary
Association/Society of Surgical Oncology/Society for Surgery of
the Alimentary Tract criteria (43) in seven studies, the
ALLIANCE criteria (44) in two studies, and other criteria (26,45–
47) in four studies. Three studies did not report staging criteria.
Most studies (n¼ 20) presented intention-to-treat results of all
BRPC patients who started with neoadjuvant FOLFIRINOX, re-
gardless of subsequent resection. Four studies included only
patients who underwent a resection after neoadjuvant treat-
ment (12,15,20,32). Eight studies included only patients with
BRPC, 11 studies combined BRPC and locally advanced pancre-
atic cancer (LAPC) patients, and five studies combined all
disease stages. For 89 patients in three studies, no distinction
could be made between BRPC or LAPC; therefore, their results
were only used for AEs and in patient-level analyses if BRPC
was confirmed by the authors (32,35,36).
FOLFIRINOX was given to 822 (45.6%) patients, of whom 313
(38.1%) patients were staged as BRPC. Only nine patients (1.1%)
from two studies had resectable pancreatic cancer (Table 1)
(12,20). Patient-level data were obtained from 20 studies reflect-
ing 283 BRPC patients, representing 90.4% of all published BRPC
patients who received neoadjuvant FOLFIRINOX.
Methodological Assessment
We included eight prospective and 16 retrospective studies. Six
studies were multicenter studies (Table 1). Results of the meth-
odological assessment of all included studies are reported in
Supplementary Table 1 (available online). The funnel plot
showed no evidence of publication bias among the included
studies (Supplementary Figure 1, available online).
Survival Analysis
Seven studies (12,13,20,25,28–30) representing 151 patients sep-
arately reported survival data for BRPC patients treated with
neoadjuvant FOLFIRINOX. The median OS for BRPC patients var-
ied across these seven studies from 11.0 to 34.2 months, and the
median PFS varied from 5.7 to 21.3 months (Supplementary
Table 2, available online).
Patient-level data were obtained for 283 BRPC patients who
received neoadjuvant FOLFIRINOX, of whom 168 (59.4%) died
during follow-up. The median follow-up of patients alive at last
follow-up was 22.9 months. The overall patient-level median OS
was 22.2 months (95% CI ¼ 18.8 to 25.6 months) (Figure 2A). The
pooled OS at 1 year was 76.0% (95% CI ¼ 70.3% to 80.7%), at
3 years 36.2% (95% CI ¼ 29.8% to 42.6%), and at 5 years 21.2%
(95% CI ¼ 14.6% to 28.6%). A total 115 of 283 patients (40.6%)
were censored. After excluding 21 patients from two studies
(20,32) that included only patients who underwent a resection,
the patient-level median OS was similar (22.2 months, 95% CI ¼
18.8 to 25.7 months, P¼ .79). No statistically significant differ-
ence was observed when comparing OS of patients in prospec-
tive (21.7 months, 95% CI ¼ 17.9 to 25.6 months) and
retrospective studies (22.4 months, 95% CI ¼ 17.7 to 27.2
months) (P¼ .36). For patients who were recurrence-free after
12 months, median OS was 43.2 months (95% CI ¼ 37.0 to 49.4
months).
For studies in which patients received a median number of
FOLFIRINOX cycles of six or fewer, the median OS was
21.4 months (95% CI ¼ 16.7 to 26.0 months) compared with
21.7 months (95% CI ¼ 15.0 to 28.4 months) for patients in stud-
ies with a median of less than six cycles (P¼ .46) (data not
shown). No statistically significant association was found be-
tween the reported median number of FOLFIRINOX cycles ad-
ministered and the patient-level median OS (Supplementary
Figure 2, available online; P¼ .05). The median OS without
upfront dose modification of FOLFIRINOX was 25.0 months (95%
CI ¼ 18.7 to 31.2 months) compared with 21.7 months (95% CI ¼
17.1 to 26.4 months) in studies with any dose modification
(P¼ .18). The median OS in studies with G-CSF prophylaxis was
20.8 months (95% CI ¼ 17.2 to 24.4 months) compared with a
median OS of 18.5 months (95% CI ¼ 13.2 to 23.8 months) in
studies in which G-CSF was prescribed at the discretion of the
treating physician (P¼ .42).
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Patient-level PFS was available for 237 BRPC patients (20
studies), of whom 144 patients (59.8%) showed progression or
died during follow-up, with a median PFS of 18.0 months (95%
CI ¼ 14.5 to 21.5 months; Figure 2B). A total 93 of 237 patients
(39.2%) were censored. After excluding the two studies (20,32)
reporting only patients who underwent a resection (n¼ 13), the
median PFS was 18.0 months (95% CI ¼ 14.6 to 21.4 months,
P¼ .99). The PFS at 1 year was 68.5% (95% CI ¼ 61.85% to 74.4%),
at 2 years 39.4% (95% CI ¼ 32.4% to 46.4%), and at 3 years 25.8%
(95% CI ¼ 19.4% to 32.6%). For prospective studies and retrospec-
tive studies, the median PFS was 18.4 months (95% CI ¼ 12.1 to
24.8 months) and 17.7 months (95% CI ¼ 14.4 to 21.0 months), re-
spectively (P¼ .60).
Chemotherapy Regimens
Details of the chemotherapy regimen used are shown in
Table 2. Only six studies reported the number of planned neoad-
juvant FOLFIRINOX cycles for BRPC patients only, ranging from
4 to 8 cycles. Eleven studies reported the median number of
FOLFIRINOX cycles administered to BRPC patients only, ranging
from 4 to 9 cycles. Of these studies, five reported a median
number of FOLFIRINOX cycles administered of six or more.
Eight studies used a dose modification as compared with the
FOLFIRINOX regimen described in the PRODIGE 4/ACCORD 11
trial (11); five studies did not include a fluorouracil bolus injec-
tion (13,27,28,34,39), four studies used a lower dose of irinotecan
(27,34,35,41), three studies did not mention inclusion of leuco-
vorin (27,28,34), and one study gave fluorouracil continuous
infusion with doses halved (14). Seven studies did not specify
the FOLFIRINOX regimen administered yet mentioned using
modified FOLFIRINOX (30), FOLFOX or FOLFIRINOX (18), or
FOLFIRINOX without mentioning upfront dose modifications
(15,20,31,32,37). Use of G-CSF was reported as primary prophy-
laxis in seven studies (13,19,28,34,37,39,41) and was prescribed
at the discretion of the treating physician in five studies
(26,27,33,38,40).
Adverse Events
AEs during treatment with FOLFIRINOX were reported in 14
studies, of which nine studies reported only pooled outcomes
across disease stages. In these 14 studies comprising 526
patients treated with FOLFIRINOX, 401 grade III or IV AEs were
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reported (Table 3). No deaths were attributed to FOLFIRINOX.
Neutropenia, diarrhea, and fatigue were the most commonly
reported grade III–IV AEs. Neutropenia had a pooled event rate
of 17.5 per 100 patients (95% CI ¼ 10.3 to 28.3, I2 ¼ 76.2%). The
pooled event rates per 100 patients for other common AEs were
16.5 (95% CI ¼ 8.4 to 29.9, I2 ¼ 0.0%) for leukopenia, 10.8 (95% CI
¼ 8.1 to 14.2, I2 ¼ 0.0%) for fatigue, 11.1 (95% CI ¼ 8.6 to 14.3, I2 ¼
0.0%) for diarrhea, 10.4 (95% CI ¼ 5.5 to 18.9, I2 ¼ 71.4%) for nau-
sea or vomiting, 8.5 (95% CI ¼ 5.2 to 13.7, I2 ¼ 0.0%) for thrombo-
embolism, and 8.9 (95% CI ¼ 6.2 to 12.5, I2 ¼ 4.3%) for
thrombocytopenia. The pooled event rate for neutropenia was
lower in six studies that administered G-CSF as primary prophy-
laxis compared with five studies with prescription of G-CSF at
the discretion of the physician (eight per 100 patients vs 23 per
100 patients, P¼ .01; forest plot in Supplementary Figure 3,
available online). The results were similar for febrile neutrope-
nia (3 per 100 patients vs 10 per 100 patients, P¼ .02; forest plot
in Supplementary Figure 4, available online).
Additional Treatment Modalities
Several studies reported the use of CRT (n¼ 8), stereotactic body
radiation therapy (n¼ 4), or intra-operative radiation therapy
(n¼ 4) besides FOLFIRINOX for at least one BRPC patient
(Table 2). Neoadjuvant CRT was given as standard additional
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Figure 2. Pooled and patient-level overall survival (OS) and progression-free survival (PFS). Pooled and patient-level (A) OS and (B) pooled and patient-level PFS were an-
alyzed. Patient-level survival outcomes were calculated from treatment initiation and analyzed using the Kaplan-Meier method. The Kaplan-Meier method was used
to account for censoring of patients alive or without recurrence at last follow-up. Pooled median OS was 22.2 months (95% confidence interval [CI] ¼ 18.8 to 25.6
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treatment for BRPC patients in three studies (13,26,39) and
reported as possible additional treatment in five other
studies (12,20,25,29,34). No correlation was found between the
percentage of (neo)adjuvant (chemo)radiation therapy and
patient-level median OS (Supplementary Figure 5, available on-
line, P¼ .14). Two studies were not included in this analysis be-
cause they included only patients who underwent a resection
(12,20).
Resection and R0 Resection Rates
Fourteen studies reported resection rates for BRPC patients
treated with neoadjuvant FOLFIRINOX (Table 2). The pooled re-
section rate was 67.8% (95% CI ¼ 60.1% to 74.6%, I2 ¼ 0.0%).
Resection margins were reported in 13 studies (Table 2). The
pooled R0 resection rate in a random-effects model was 83.9%
(95% CI ¼ 76.8% to 89.1%, I2 ¼ 0.0%).
Discussion
This patient-level meta-analysis of 20 studies representing 283
patients who received neoadjuvant FOLFIRINOX for BRPC
showed a median OS of 22.2 months (95% CI ¼ 18.8 to 25.6
months). After neoadjuvant FOLFIRINOX, 67.8% (95% CI ¼ 60.1%
to 74.6%) of patients underwent a curative-intent resection with
an R0 resection rate of 83.9% (95% CI ¼ 76.8% to 89.1%). The rate
of grade III or IV AEs was high, but no death was attributed to
FOLFIRINOX.
FOLFIRINOX has been studied for patients with advanced
pancreatic cancer since 2005 (48). For metastatic pancreatic
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cancer, palliative FOLFIRINOX has been the standard of care for
patients with a good performance status since an RCT found a
median OS of 11 months vs 7 months with gemcitabine (11). In
patients with LAPC, no RCT has been published for induction
chemotherapy with FOLFIRINOX. The best available evidence of
FOLFIRINOX for LAPC is a systematic review and patient-level
meta-analysis of 315 patients (11 studies) that found a median
OS of 24.2 months (95% CI ¼ 21.7 to 26.8 months) (49). Figure 3
compares the patient-level OS of patients who received
FOLFIRINOX in the setting of BRPC (present study) and LAPC
(49). OS for both groups is clearly superior to OS for patients
treated with FOLFIRINOX for metastatic pancreas cancer in the
RCT of Conroy et al. (11). It is remarkable that the median OS of
22.2 months for BRPC patients in this study is similar to the
24.2 months in the LAPC setting. The survival curves of LAPC
and BRPC overlap for the initial 2 years, after which they di-
verge. OS after 3 years was 36.2% for BRPC vs 23.0% for LAPC
patients. The difference in local extent of the disease between
BRPC and LAPC appears to be irrelevant for about one-half of
the patients who die within 2 years. The difference in OS after
2 years probably reflects both less advanced disease and a
higher resection rate for BRPC (68% vs 27% in the LAPC setting)
(49).
The use of radiation therapy after neoadjuvant FOLFIRINOX
varied across studies. At the study level, no association was
found between the percentage of patients who received neoad-
juvant (chemo)radiation and median OS (Supplementary Figure
3, available online). Versteijne et al. performed a meta-analysis
of intention-to-treat outcomes of any neoadjuvant approach vs
upfront resection for (borderline) resectable pancreatic cancer
[(B)RPC]. In a subgroup analysis comparing neoadjuvant
approaches with and without radiation therapy, they also found
no difference in OS (50). The interim analysis of the Dutch
PREOPANC-1 trial, as presented at the ASCO annual meeting in
2018, showed a twofold increase in R0 resection rate, with 31%
after upfront resection vs 65% after neoadjuvant CRT (P< .001)
(51). Although the impact of RT on local control is convincing, it
remains uncertain whether this translates into superior OS.
Many studies have found favorable OS for patients who un-
dergo a resection of BRPC after neoadjuvant chemo(radio)ther-
apy (52). However, some studies overestimated OS with
neoadjuvant treatment, because OS was only reported for
patients who underwent a curative-intent resection after neo-
adjuvant treatment, whereas patients who had progressive dis-
ease before resection were excluded. A recent meta-analysis
resolved this selection bias by including only studies that ad-
hered to the intention-to-treat principle: all patients who
started neoadjuvant treatment were included in the analyses,
regardless of whether they underwent a resection (50). Only 3%
of these patients received neoadjuvant FOLFIRINOX. The
authors found a superior median OS for any neoadjuvant ap-
proach (18.8 months) compared with upfront surgery
(14.8 months) in (B)RPC patients. In 2018, the first two RCTs for
neoadjuvant treatment of (B)RPC completed accrual (51,53). A
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Figure 3. Pooled overall survival for patients with borderline resectable, locally advanced, and metastatic pancreatic cancer. For the survival curve of the locally ad-
vanced pancreatic cancer patients, patient-level data from the meta-analysis Suker et al. (49) was used. For the estimation of the survival curve for the metastatic pan-
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Korean trial was closed prematurely when interim analysis
found a superior median OS of 21 months for neoadjuvant CRT
vs 12 months with upfront surgery and adjuvant CRT (P¼ .028)
(53). The previously mentioned interim analysis of the
PREOPANC-1 trial found a median OS of 17.1 months with neo-
adjuvant gemcitabine-based CRT vs 13.7 months with upfront
surgery and adjuvant gemcitabine (P¼ .074) (51). However, nei-
ther RCT investigated neoadjuvant FOLFIRINOX.
Because FOLFIRINOX is a more effective regimen than gem-
citabine alone in the metastatic setting, it is expected that it fur-
ther improves OS for patients with (B)RPC in the neoadjuvant
setting. Four RCTs evaluating neoadjuvant FOLFIRINOX are cur-
rently accruing patients: the phase II ALLIANCE A021501 trial
(NCT02839343) initially compared neoadjuvant mFOLFIRINOX
with or without hypofractioned radiation therapy for BRPC, but
recently closed the radiation therapy arm because it met the
predetermined futility boundary for R0 resection (54); the phase
III NorPACT-1 trial (NCT02919787) for resectable pancreatic can-
cer comparing neoadjuvant FOLFIRINOX with upfront surgery,
both followed by adjuvant gemcitabine and capecitabine (55); the
phase II PANACHE01-PRODIGE48 trial (NCT02959879) for resect-
able pancreatic cancer comparing neoadjuvant FOLFIRINOX with
neoadjuvant FOLFOX chemotherapy and upfront surgery, all fol-
lowed by adjuvant chemotherapy (56); and the phase III
PREOPANC-2 trial (NTR7292) comparing neoadjuvant FOLFIRINOX
with neoadjuvant gemcitabine-based CRT for (B)RPC (57). Final
results of these trials are not anticipated within the next 5 years.
Meanwhile, experienced centers continue to publish impressive
results in retrospective studies of neoadjuvant FOLFIRINOX for
BRPC and LAPC. Most recently, Michelakos et al. published the
updated series of Massachusetts General Hospital. For the com-
bined group of BRPC and LAPC patients who underwent a resec-
tion after neoadjuvant FOLFIRINOX, they found a median OS of
37.7 months from diagnosis (58).
Median OS estimates after neoadjuvant treatment for BRPC
may appear inferior to outcomes with adjuvant chemotherapy.
For example, the ESPAC-4 trial reported a median OS of
28.0 months in the adjuvant gemcitabine-capecitabine arm (59).
Moreover, the recent PRODIGE 24/CCTG PA.6 trial reported a me-
dian OS of 54.4 months in the adjuvant FOLFIRINOX arm (60).
However, the patient populations of a neoadjuvant trial and an
adjuvant trial are highly different and cannot be compared di-
rectly. To be eligible for an adjuvant trial, a patient has to over-
come several hurdles. A small percentage of patients will never
make it to the operating room, often because of a combination
of drainage-related complications (eg, cholangitis or pancreati-
tis) and frailty. Moreover, about 20% of radiographically BRPC
patients will never undergo resection because of occult meta-
static disease at staging laparoscopy or unexpected LAPC during
surgical exploration (61,62). Finally, most adjuvant trials require
a complete macroscopic resection, a CA 19–9 level below 180 U/
mL, and full recovery from surgery within 12 weeks after resec-
tion. In large nationwide studies, only about 55% of patients re-
ceived adjuvant chemotherapy (4–6). Neoadjuvant trials include
all those patients who drop out during treatment; only about
one-third of these patients would be eligible for adjuvant trials
after undergoing a resection and remaining fit for adjuvant che-
motherapy. Excluding the worst two-thirds of patients will obvi-
ously have a major impact on the median OS.
After neoadjuvant FOLFIRINOX, resection rates ranged from
50% to 100% across studies. This substantial heterogeneity may
be explained by the lack of consensus regarding resectability
criteria and criteria to proceed with surgery after neoadjuvant
treatment. Reaching consensus on resectability criteria is
needed to improve comparison in future studies. In the pooled
analysis of the present study, we found a resection rate of 68%.
A similar resection rate of 66% was found in an intention-to-
treat meta-analysis of (B)RPC patients treated with any neoadju-
vant CRT regimen (50). The pooled R0 resection rate of 84% in
the present study was higher compared with the intention-to-
treat R0 resection rate of 67% with upfront surgery (50).
Some limitations of the present study should be considered.
Although the present study represents the best available esti-
mate of survival after neoadjuvant FOLFIRINOX for BRPC
patients, it might be an overestimate because of the retrospec-
tive nature of most included studies. Similarly, secondary study
endpoints such as AEs and PFS were prone to selection and in-
formation bias. Heterogeneity across studies also might have bi-
ased the results; studies used different resectability criteria,
FOLFIRINOX regimens, and additional treatment (eg, CRT).
In conclusion, this patient-level meta-analysis of BRPC
patients treated with neoadjuvant FOLFIRINOX showed a favor-
able median OS, resection rate, and R0 resection rate. These
results need to be assessed in a randomized trial.
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